Kornimate/medical-research-clean huggingface dataset:
taylor swift and mental health outcomes

Conditions: Social Stigma; Psych; Depression, Anxiety; Stress

Summary: a study in singapore will explore the potential of pop culture, particularly taylor swift's music, in influencing young adults' attitudes toward mental health. with the highest prevalence of mental illness among this age group, the study will aim to investigate whether engagement with swift's songs and social media will be associated with attitudes crucial for help-seeking, such as recognizing mental health issues and being open to professional services. conducting a survey of over 600 young adults, the researchers will assess participants' mental health symptoms, engagement with swift's content, social media and demographics, mental health help-seeking attitude and mental health self-diagnosing behavior.

background: epidemiological surveys suggest that young adulthood is the age group with the highest prevalence of mental illness. however, many young adults have negative views towards help-seeking and do not access professional services. to address this gap, popular culture may provide population-level levers to improve mental health outcomes. objective: in this study, we will focus on taylor swift - a singer whose songs explore themes related to mental health. as the first objective, we will seek to understand whether young adults will feel a personal connection to her mental health-themed songs and follow her on social media. we will then examine whether these forms of engagement will predict attitudes critical for help-seeking: namely, acknowledgement that one may have a mental illness, and willingness to seek professional services as needed. methods: in the months leading up to taylor swift's concerts, we will conduct a survey of over 600 young adults in singapore (aged 18 to 34). as the primary outcome measures, participants will complete the self-identification as having mental illness scale (selfi) and the inventory of attitudes toward seeking mental health services scale (iasmhs). as predictor variables, participants will answer questions related to: (i) their baseline symptoms of depression, anxiety, and stress; (ii) their engagement with taylor swift's songs and social media content; and (iii) their demographics.

Eligibility criteria:
inclusion criteria: * enrollment is restricted to healthy adults between 18-34 * use at least one of the following social media platforms: facebook, instagram, linkedin, x (twitter), tiktok * have lived in singapore for at least 2 years. * participants need to be able to read and understand english. exclusion criteria: * anyone who does not feel comfortable answering questions related to mental health and exposure to mental health-related content online.

Keywords: pop-culture music mental health literacy adolescent health
a multiple-ascending-dose study to evaluate the efficacy, safety, and pharmacokinetics (pk) of medi0382 in overweight and obese participants with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: a phase 1/2, multiple dose study with 6 cohorts of ascending doses designed to evaluate the efficacy, safety and pharmacokinetics (pk) of medi0382 in participants with type 2 diabetes mellitus (t2dm).

this is a randomized, double-blind, placebo controlled study designed to evaluate the efficacy, safety, and pk of medi0382 administered as multiple daily sc doses to participants with t2dm. approximately one hundred and seven participants will be enrolled across 6 cohorts. in cohorts 1-3 the participants will be randomized to medi0382 or placebo (2:1). in cohort 4, participants will be randomized to medi0382 or placebo (1:1). in cohort 5 and 6 participants will be randomized to medi0382 or placebo (3:1).

Eligibility criteria:
inclusion criteria: * diagnosis of t2dm * must provide written informed consent * body mass index greater than (\>) 27 and less than (\<) 40 kg/m\^2, inclusive * venous access suitable for multiple cannulations * vital signs within normal specified ranges * females must be non-lactating and non-childbearing potential * males must practice 2 effective contraceptive measures if sexually active exclusion criteria: * any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the investigational product * history or presence of gastrointestinal, renal, or hepatic disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs * history of cancer within the last 10 years, with the exception of non-melanoma skin cancer * any clinically important illness (except for t2dm), medical/surgical procedure, or trauma within 4 weeks prior to dosing * fasting glucose greater than or equal to (\>=) 200 mg/dl * positive hepatitis b, hepatitis c or human immunodeficiency virus test or use of antiretroviral medications at screening. * concurrent or previous use of a glucagon-like peptide 1 receptor agonist * current or previous use of systemic corticosteroids within the past 28 days prior to screening * use of any medicinal products or herbal preparations licensed for control of body weight or appetite is prohibited. * known or suspected history of alcohol or drug abuse within the past 3 years. * positive drug screen

Keywords: medi0382, diabetes
change of gut microbiome and symptom after h.pylori eradication therapy in patients with functional dyspepsia

Conditions: Dyspepsia

Summary: the aims of the investigators' study are to investigate the effect of h.pylori eradication on the human gut microbiome and symptoms of functional dyspepsia.

accumulating evidence shows that helicobacter pylori protects against some metabolic and immunological diseases in which the development of these diseases coincide with temporal or permanent dysbiosis. helicobacter pylori eradication therapy has the potential to improve symptoms of functional dyspepsia. the aims of our study are to investigate the effect of h.pylori eradication on the human gut microbiome and symptoms of functional dyspepsia.

Eligibility criteria:
inclusion criteria: * patients who has diagnosed with functional dyspesia by rome iv criteria exclusion criteria: * known gi malignancy * previous helicobater pylori eradication history * severe systemic disease * previous gi surgery * uncorrectable coagulopathy: inr \> 1.5 or platelet \< 50,000/ml * pregnant or breastfeeding women * atrophic gastritis, open type

Keywords: dyspepsia microbiome eradication therapy
combined treatment of manual therapy and therapeutic exercise in patients with low back pain

Conditions: Low Back Pain, Mechanical; Musculoskeletal Manipulations; Exercise Training

Summary: main objective: to assess whether an exercise protocol on the lumbar musculature by adding manual therapy techniques on the diaphragm muscle has the same or greater effect on chronic non-specific lumbar pain than an isolated exercise protocol. secondary objectives: to evaluate the effectiveness of a lumbar exercise protocol in chronic non-specific low back pain in isolation; to evaluate the effectiveness of both therapies in improving joint range in patients with chronic non-specific low back pain and, finally, to assess catastrophism and the avoidance of lumbar mobility when carrying out loaded movements. hypothesis: that a lumbar exercise protocol combined with manual therapy treatment on the diaphragm is equal or more effective on pain in patients with chronic nonspecific low back pain than treatment with the same lumbar exercise protocol in isolation.

methodology: a prospective randomized clinical trial with two types of intervention (lumbar exercise protocol and manual diaphragm therapy) will be carried out. the variables to be measured are pain, disability, mobility and kinesiophobia. it will be performed in two groups of 21 people who are of legal age, who have low back pain of more than 3 months duration and which is of non-specific origin. the patients will be randomized and divided into two groups a (control) and b (experimental). group a will undergo an exercise protocol. group b will undergo the same protocol plus manual therapy techniques on diaphragm muscle. study participants will have treatment twice a week for 8 weeks, the first information session and the second measurement-evaluation session in the first week of treatment. in the following 3 weeks the session will last 40 minutes for both groups. in the 4th week the established measurements will be carried out again.

Eligibility criteria:
inclusion criteria: * legal age * non-specific low-back pain * pain more 3 months exclusion criteria: * subjects with lumbar herniation. * spine canal stenosis * subjects with neurological disease. * lumbar surgery
characterisation of clinical phenotypes and outcomes of ma2 patient

Conditions: Autoimmune Encephalitis; Paraneoplastic Syndromes

Summary: paraneoplastic neurological syndromes (pns) are rare complications of cancer occurring in 0.01% of cases. their clinical, biological and radiological presentation is heterogeneous and may constitute a diagnostic challenge. anti-ma2 pns are rare diseases with a guarded prognosis. they are most often associated with a seminoma-like testicular tumor but can also be associated with lung cancer. classically, they present as limbic, diencephalic and/or brainstem encephalitis. anti-ma2 antibodies target intracellular receptors and are characteristic of a particular form of encephalitis. atypical manifestations including narcolepsy-cataplexy, weight gain, sexual dysfunction and motor neuron syndrome have been described and explain the difficulty in diagnosing anti-ma2 associated pns. it seems interesting to better characterize the phenotypes of ma2 patients in order to optimize the diagnosis and follow-up.


Eligibility criteria:
inclusion criteria: * neurological disorder * anti-ma2 positivity in sera or csf * patient \> 18 years old exclusion criteria: * patient without clinical data * patient without ma2 antibody in sera or csf

Keywords: neurological paraneoplastic syndrome auto immune encephalitis ma2 antibody
diabetes in minor stroke/tia, glucose tolerance and haemostasis, a long-term-follow-up study and intervention with yoga

Conditions: Stroke; TIA

Summary: in acute stroke patients about 20 % have known diabetes. there is a doubled risk of recurrent stroke in diabetic patients. it has been shown that antiplatelet drugs are not as effective in diabetic patients as in non-diabetic patients. in acute stroke patients around 80 % have impaired glucose tolerance, which will improve after one month till about 60 %. this study includes acute patients with minor stroke or tia. they are followed up at one and six months and then at every six months for at least four years. the investigators perform an ogtt and haemostatic tests within the first days after onset and then at one month. blood pressure, metabolic parameters, bodyweight, physical activity and diet are collected at each visit. the investigators give the patients information about lifestyle changes as needed. as part of the study there is an interventional study, medicine yoga, an open randomized controlled study. patients are randomized to 16 sessions of yoga under professional instructions and a cd for home training or controls. the aims of this study are to investigate glucose tolerance in acute stroke and tia patients, and its relation to the different haemostatic variables. the importance of glucose tolerance, haemostatic variables and other risk factors (blood pressure, lipids, bmi,) on cardiovascular events will be investigated and the possibility to affect these risk factors by lifestyle changes and yoga. the effect of different antiplatelet drugs will be investigated in relation to glucose tolerance.

144 patients with minor stroke and tia has been included in the study between 2010 and 2012. they have been follow for four years. two papers have been published on the results of the study. lundström a, von arbin m, laska a c, jörneskog g, wallen nh. glucose intolerance and insulin resistance as predictors of low platelet response to clopidogrel in patients with minor ischemic stroke or tia. platelets. 2013 mar 25.341-49. lundström a, wallén h, von arbin m, jörneskog g, gigante b, höeg embrower k, laurencikas e, laska ac. clopidogrel resistance after minor ischemic stroke or transient ischemic attack is associated with radiological cerebral small-vessel disease. j stroke cerebrovasc dis. 2015 aug 21. pii: s1052-3057(15)00349-3

Eligibility criteria:
inclusion criteria: * acute minor stroke and tia patients able to perform ogtt within the first days after onset or having known diabetes. exclusion criteria: * terminal disease
teriflunomide male transmission study

Conditions: Multiple Sclerosis

Summary: it is known that teriflunomide, a treatment for relapsing forms of multiple sclerosis, can be found in low concentrations in semen. because the drug has been associated with teratogenicity in laboratory animals, the question is raised as to whether the drug can be detected in female partners of sexually active males who are taking the drug to treat their multiple sclerosis.

a total of 10 couples were enrolled in the study. females partners had undetectable or borderline levels of teriflunomide.

Eligibility criteria:
inclusion criteria: 1. males with relapsing forms of multiple sclerosis appropriately treated with teriflunomide 14 mg po daily; 2. continuous treatment for three months with good compliance as assessed by the investigator 3. age between 18 and 55 4. penile-vaginal intercourse with a female partner at least twice a month with unimpeded ejaculation. 5. compliance with safety assessments, e.g., regular bloodwork for complete blood count and liver function testing as recommended in the package insert 6. able to give informed consent females 1. regular sexual intercourse with a male partner who is actively taking teriflunomide 2. age between 18 and 55 3. able to give informed consent 4. negative urine pregnancy test at the time of blood sampling 5. reliable contraception that does not involve barrier methods exclusion criteria: 1. use of barrier methods of contraception 2. for males, contraindications to the continued use of teriflunomide 3. couples that are actively trying to conceive 4. for males, noncompliance with teriflunomide therapy 5. inability or unwilling to give consent or comply with the protocol 6. pregnancy of the female sexual partner.
acute high-risk abdominal surgery study - an optimized perioperative course

Conditions: Perforated Viscus; Intestinal Obstruction

Summary: the objective of this study is to implement an optimized perioperative course for patients undergoing acute high-risk abdominal surgery in order to improve the outcome. the optimized perioperative course consists of a number of interventions carried out before, during and after surgery.

emergency surgery is associated with high mortality rates, post-operative complications and prolonged duration of hospital admission. the investigators will implement a multidisciplinary optimized perioperative course consisting of a number of interventions carried out before, during and after surgery. hypothesis: an optimized perioperative course will reduce the 30-day mortality in emergency abdominal surgery patients. the investigators will do a post-hoc analysis of the data registered.

Eligibility criteria:
inclusion criteria: * patients undergoing primary emergency laparotomy or laparoscopy * patients undergoing reoperation after abdominal surgery. * age \> 18 years exclusion criteria: * appendectomy * emergency laparoscopic cholecystectomy * emergency diagnostic laparoscopy without intervention

Keywords: emergency laparotomy emergency laparoscopy
a study of the pan-kras inhibitor ly4066434 in participants with kras mutant solid tumors

Conditions: Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumor; Metastatic Solid Tumor

Summary: the main purpose of the study is to assess whether the study drug, ly4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain kras mutations. ly4066434 will be given alone or in combination with other treatments. the study will have 2 parts: monotherapy dose escalation and dose optimization. the study is expected to last up to approximately 5 years.


Eligibility criteria:
inclusion criteria: * have evidence of kras g12c, g12d, g12v, g12a, g12s, or g13d mutation in tumor tissue or circulating tumor dna * histological or cytologically proven diagnosis of a locally advanced, unresectable, and/or metastatic solid tumor cancer * have measurable disease per recist 1.1 * have an ecog performance status of ≤1 * must not be pregnant and/or planning to breastfeed during the trial or within 180 days of the last dose of trial intervention * must be able to swallow tablets * participants with asymptomatic or treated cns disease may be eligible exclusion criteria: * have known active cns metastases and/or carcinomatous meningitis * have any unresolved toxicities from prior therapy greater than nci ctcae version 5.0 grade 1 at the time of starting trial treatment, except for alopecia, peripheral neuropathy and ongoing endocrinopathies controlled on appropriate replacement therapy * have significant cardiovascular disease defined as unstable angina or acute coronary syndrome, history of myocardial infarction, known left ventricular ejection fraction or heart failure, uncontrolled or symptomatic arrhythmias. * have known active hepatitis b virus (hbv), hepatitis c virus (hcv) and untreated hiv infection * have other active malignancy unless in remission with life expectancy greater than 2 years. * have active uncontrolled systemic bacterial, viral, fungal, or parasitic infection * have history of non-infectious pneumonitis/interstitial lung disease that received steroids or has current clinically significant pneumonitis/interstitial lung disease

Keywords: kras kras mutation krasg12c krasg12d krasg12v krasg12s krasg12a krasg13d ly4066434 targeted therapy lung cancer pancreas cancer colon cancer rectal cancer colorectal cancer ovarian cancer endometrial cancer cholangiocarcinoma esophageal cancer kras-mutant tumor
timing of suture removal to reduce scarring in skin surgery

Conditions: Suture Related Complication

Summary: this is a single centre prospective randomized assessor blinded parallel group feasibility study that will be undertaken in the royal devon and exeter dermatology department. the investigators will be looking at whether timing of percutaneous suture removal after skin surgery impacts on the incidence of suture marks and overall scar cosmesis.

stitch marks (also known as suture marks or track marks) are permanent marks left in the skin where the stitch has caused local tissue damage and scarring. the risk of these marks is in part thought to be related to the length of time that the stitches are left in place before removal. stitches are normally left in place for longer on sites where the skin is under greater tension such as the chest or back because there is a concern that the wound may be more likely to open up on these sites. on the chest or back, stitches may be left in place for up to 14 days even though the chest or back is a common site for stitch marks to form. the investigators are conducting a single centre prospective randomized assessor blinded parallel group feasibility study to estimate a sample size required for a properly powered rct, and also to provide some preliminary data on the incidence of wound complications and overall scar cosmesis in each group. all patients attending the dermatology department for wide local excision as part of their skin cancer treatment and primary closure of the subsequent wound will be considered for entry into the trial. clinicians will identify potential participants during routine practice at their clinic visit. patients who fulfil the entry criteria will be invited at that appointment to take part. on the date of participants skin surgery, they will be consented and randomized to either 'suture removal at 7 days' or 'suture removal at 10 days'. participants will then be booked for a 3 month follow up where the scar site will be evaluated from a patient and clinician perspective to assess suture marks and overall cosmesis.

Eligibility criteria:
inclusion criteria: * patients of 18 years old or above who had capacity to consent to surgery who were willing to attend follow-up appointments within the department * patients undergoing wide local excision as part of their skin cancer treatment pathway * lesions excised from the anterior chest or back * post-operative wound \>/= 10mm width * wound could be closed with primary intention healing exclusion criteria: * inability to provide valid informed consent and/or unwilling to attend for follow-up * wounds where the edges could not be closely adhered with dermal sutures alone. * wounds requiring a flap or graft for closure. * patients requiring further treatment following original excision eg. further wle, radiotherapy etc.
clinical characteristics of patients developing chronic dry eye after refractive surgery

Conditions: Dry Eye

Summary: in recent years, many scholars have studied the ocular surface damage of patients with dry eye disease（ded）after fs-lasik, but there has been a lack of comprehensive observation and research on the relationship and difference between dry eye （de）patients with and without lasik. therefore, the purpose of this study was to investigate the characteristics of ocular surface and cytokines after fs-lasik, and further explain the pathogenesis of chronic dry eyes after fs-lasik. in addition, we will also compare clinical characteristics and tear neuropeptide concentrations in patients with dry eye disease (ded) with and without chronic ocular pain following fs-lasik, and to investigate correlations between ocular pain, clinical characteristics, and tear neuropeptide levels.

a single visit cross-sectional study was performed. approximately 40 chronic dry eye participants who had fs-lasik more than 12month prior were recruited. approximately 40 dry eye participants without refractive surgery history and 40 healthy participants without dry eye were also recruited as control groups. in addition, the patients with post-fs-lasik ded were categorized into two groups based on the presence or absence of chronic ocular pain: (1) post-fs-lasik ded patients with chronic ocular pain and (2) post-fs-lasik ded patients without chronic ocular pain.

Eligibility criteria:
inclusion criteria: 1. age 18years to 40 years 2. male or female 3. ded patients based on chinese dry eye diagnosis standard (2020) with or without fs-lasik 4. provision of written informed consent. exclusion criteria: 1. active ocular infection, ocular inflammation, active ocular allergy, severe blepharitis or obvious inflammation of the eyelid margin, which in the judgment of the investigator may interfere with the interpretation of the study results. 2. pregnant and lactating women, or those planning a pregnancy over the course of the study 3. uncontrolled systemic disease 4. suffer from diseases that may affect corneal nerves, such as keratoconus, trigeminal neuralgia, allergic conjunctivitis, etc.